Annovis Bio Inc ANVS 深 沪
已收盘 01-30 16:00:00 美东时间
2.70
-0.110
-3.91%
华盛通- 最 高2.88
- 今 开2.80
- 成交量 53.42万股
- 最 低 2.60
- 昨 收 2.81
- 总市值 7155.78万
- 52周最高 5.50
- 市盈率 静 --
- 换手率 2.02%
- 52周最低 1.11
- 委 比 26.74%
- 总股本 2650.29万
- 历史最高 132.00
- 量 比 1.24
- 振 幅 9.96%
- 历史最低 1.11
- 每 手 1
- 风险率 0.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Annovis Bio Advances Long-Term Buntanetap Safety Study in Parkinson’s Disease
Annovis Bio Inc ($ANVS) announced an update on their ongoing clinical study. St...
2025-12-19 00:31
Annovis to Host Corporate Update Webinar on January 28, 2026
Annovis Bio, Inc. will host a corporate update webinar on January 28, 2026, featuring Maria Maccecchini, Ph.D., President and CEO, discussing the Company’s recent progress, clinical programs, and strategic directions. The webinar is open to shareholders, patients, and interested parties, with a live Q&A session. Registration is available via the provided link, and pre-submitted questions can be sent to ir@annovisbio.com.
2025-12-16 13:00
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
<p>Annovis Bio, a company developing treatments for neurodegenerative diseases, announced its participation in the 2025 Parkinson Study Group Annual Meeting in San Diego, where it will present data on its drug, buntanetap. The presentation will highlight recent Phase 3 findings showing that buntanetap counteracts cognitive decline and reduces tau biomarkers in Parkinson’s disease patients with amyloid co-pathology. Additionally, cross-study compa...
2025-12-03 13:00
美股牛股 | 绩优股集体大爆发！柯尔百货暴涨超42%，连续两季度上调业绩指引；Symbotic大涨近40%
绩优股集体大爆发！柯尔百货暴涨超42%，连续两季度上调业绩指引；Symbotic大涨近40%，年内涨幅达226%>>
2025-11-26 16:15
Annovis Announces Two Presentations at the CTAD 2025 Conference
Annovis Bio, Inc. will present two studies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) conference in San Diego. The presentations will focus on buntanetap, a potential disease-modifying therapy for Alzheimer's and Parkinson's diseases. Presentation P073 by Cheng Fang, Ph.D., will discuss amyloid co-pathology and cognitive decline in Parkinson's dementia patients treated with buntanetap, while Presentation P007 by Maria Maccecchini, ...
2025-11-24 13:00
Annovis Bio Data From Phase 3 Trila In Early Parkinson's Demonstrates Buntanetap Halted Cognitive Decline Across Overall Patient Count
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's
2025-11-17 21:01
Annovis Bio GAAP EPS of -$0.37
Annovis Bio press release (ANVS): Q3 GAAP EPS of -$0.37. Annovis’ cash and cash equivalents totaled $15.3 million as of September 30, 2025, compared to $10.6 million as of December 31, 2024. More on A...
2025-11-12 22:18
Annovis Bio Q3 EPS $(0.37) Misses $(0.30) Estimate
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 21.31 percent. This is a 61.86 percent increase over losses of $(0.97) per share from the
2025-11-12 21:11
Annovis Bio Says All 84 Facilities For Pivotal Phase 3 Trial In Early Alzheimer's Disease Activated, First Group Of Patients Reaches 6-Month Treatment Milestone
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's
2025-11-06 21:08
Annovis launches $6 million registered direct offering
Annovis Bio (NYSE:ANVS) has entered into definitive agreements for the purchase of an aggregate of 4M shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 p...
2025-10-10 20:58
